Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Akiyuki Suzuki"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 9, Pp 1358-1370 (2023)
Abstract Tanezumab is a monoclonal antibody against nerve growth factor (NGF). We investigated tanezumab pharmacokinetic (PK)‐NGF relationships and predicted the extent of systemic free NGF suppression with target‐mediated drug disposition (TMDD)
Externí odkaz:
https://doaj.org/article/1ab8ebe565ec4b34903a44df2b2b5735
Publikováno v:
Animals, Vol 14, Iss 16, p 2412 (2024)
This study investigates the captive environments of oriental small-clawed otter (OSO; Aonyx cinereus) cafés in Japan, aiming to identify discrepancies with established welfare guidelines. Improved management of these commercial facilities could rais
Externí odkaz:
https://doaj.org/article/ea09b6b04acf480690faf6ecafa8e475
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 5, Pp 505-512 (2019)
In Japan, the Pharmaceuticals and Medical Devices Agency requires all‐case surveillance studies (ACSS) for many novel oncology drugs as a condition for approval. However, this is a major burden on the pharmaceutical industry and clinicians. The obj
Externí odkaz:
https://doaj.org/article/77a1fa363ad8493eacbe235ef7db390d
Autor:
Mari Nakatani, Masahiko Nakamura, Akiyuki Suzuki, Takamasa Fuchikami, Munenori Inoue, Tadashi Katoh
Publikováno v:
ARKIVOC, Vol 2003, Iss 8, Pp 45-57 (2003)
Externí odkaz:
https://doaj.org/article/b78819d8d39a4239b23d48da8829f9b6
Publikováno v:
British Journal of Clinical Pharmacology. 88:3321-3334
Describe population pharmacokinetics of intravenous (IV) and subcutaneous (SC) tanezumab across Phase 2b/3 studies of osteoarthritis and chronic low back pain.Data from 10 studies of IV or SC tanezumab (2.5-20 mg every 8 wk for up to 56 wk) were incl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edc864660a18147b0d29463ab740c507
https://doi.org/10.1111/bcp.15259
https://doi.org/10.1111/bcp.15259
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 5, Pp 505-512 (2019)
Clinical and Translational Science
Clinical and Translational Science
In Japan, the Pharmaceuticals and Medical Devices Agency requires all-case surveillance studies (ACSS) for many novel oncology drugs as a condition for approval. However, this is a major burden on the pharmaceutical industry and clinicians. The objec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edcee64f85738042903afe7268c9dcb8
https://doaj.org/article/77a1fa363ad8493eacbe235ef7db390d
https://doaj.org/article/77a1fa363ad8493eacbe235ef7db390d
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Objective: Bococizumab, a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9, has been shown to reduce low-density lipoprotein cholesterol (LDL-C). Here, we describe the pharmacokinetics and pharmacodynamics of bococizumab an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c96d13544d0ecde99844828e55cacf12
https://pubmed.ncbi.nlm.nih.gov/31549625
https://pubmed.ncbi.nlm.nih.gov/31549625
Autor:
Akiyuki Suzuki
Publikováno v:
YAKUGAKU ZASSHI. 136:537-542
According to the US Food and Drug Administration, pharmacometrics is an emerging science that quantifies drugs, diseases, and trial information to aid efficient drug development and/or regulatory decisions. Quantitative decision making occurs at all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb5e655563b499e1b18030690945beb1
https://doi.org/10.1248/yakushi.15-00224-3
https://doi.org/10.1248/yakushi.15-00224-3
Autor:
Toshihiko Doi, Yosuke Fujii, Kiyotaka Yoh, Kyung-Hun Lee, Atsushi Ohtsu, Tomoko Hirohashi, Yung-Jue Bang, J. A. Williams, Akiyuki Suzuki, Tae Yong Kim, Corrado Gallo Stampino, Tae Min Kim, Masafumi Ikeda
Publikováno v:
Cancer Medicine
Preclinical studies suggest that ALK‐1 signaling mediates a complementary angiogenesis pathway activated upon development of resistance to vascular endothelial growth factor (VEGF)‐targeted therapies. Inhibition of ALK‐1 signaling may lead to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf2f7226d9e6c705152409d90a46d2a0
http://europepmc.org/articles/PMC4944871
http://europepmc.org/articles/PMC4944871
Autor:
Yoshiko Umeyama, Michael A. Tortorici, Robert R. LaBadie, Yazdi K. Pithavala, Akiyuki Suzuki, May Garrett, Ying Chen
Publikováno v:
Investigational New Drugs. 33:521-532
Axitinib, a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, showed improved progression-free survival over sorafenib in patients previously treated for advanced renal cell carcinoma in the A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29698cbc29e8c80eea352f0f87ae273b
https://doi.org/10.1007/s10637-015-0214-x
https://doi.org/10.1007/s10637-015-0214-x